Phase 3 Trials for Antiamyloid Gantenerumab Show Poor Results.

Published Date: 25 Nov 2023

The antiamyloid monoclonal antibody gantenerumab reduced the burden of amyloid plaque in early-stage Alzheimer's disease patients, but there was no discernible cognitive benefit in twin pivotal trials.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belgian Algorithm Reshapes Endometrial Cancer Care

2.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

3.

Nuclear missile workers are contracting cancer: They blame the bases

4.

On all CAR-T products, the FDA is calling for a new boxed warning.

5.

ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot